NURS 5334 ADVANCED PHARMACOLOGY NP BOARD EXAM
BUNDLED QUIZ 1,2,3,4,5,6,7,8 & AND CORRECT ANSWERS PLUS
RATIONALE WELL ILLUSTRATED NEW UPDATE 2026-2027 UTA
49 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to individualize drug therapy across diverse
patient populations
2 Analyze drug-drug, drug-disease, and drug-gene interactions to prevent adverse outcomes and optimize
therapeutic regimens
3 Synthesize current national guidelines and evidence to select, monitor, and adjust pharmacologic therapy
for acute and chronic conditions
4 NURS 5334 Advanced Pharmacology NP Board Exam BUNDLED Quiz 1
5 8 & and Correct Answers plus Rationale Well Illustrated New Update 2026
6 2027 UTA
7 Foundations of Advanced Pharmacology for Nurse Practitioners
8 Applied Advanced Pharmacology for Nurse Practitioners
9 Advanced Advanced Pharmacology for Nurse Practitioners
10 Advanced Pharmacology for Nurse Practitioners Review
ABSTRACT
This study document brings together 49 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology NP Board Exam BUNDLED Quiz 1,2,3,4,5,6,7,8 & and Correct Answers
plus Rationale Well Illustrated New Update 2026-2027 UTA, with the strongest emphasis placed on
Apply pharmacokinetic and pharmacodynamic principles to individualize drug therapy across
diverse patient populations, Analyze drug-drug, drug-disease, and drug-gene interactions to
prevent adverse outcomes and optimize therapeutic regimens, Synthesize current national
guidelines and evidence to select, monitor and and adjust pharmacologic therapy for acute and
chronic conditions. Every item follows the wording style and level of reasoning you meet in the real
paper, and each one is paired with a clear rationale so the correct choice is never a guess. Work
through the set at your own pace, mark the questions that slow you down, then come back to them
until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient with heart failure with reduced ejection fraction (HFrEF) is initiated on
sacubitril/valsartan. Which mechanism best explains the need for a 36-hour
washout period when transitioning from an ACE inhibitor?
A. Prevention of bradykinin accumulation and angioedema CORRECT
B. Avoidance of hyperkalemia from dual RAAS blockade
C. Reduction of hypotension from combined vasodilation
D. Prevention of renal function deterioration from prostaglandin inhibition
RATIONALE: ACE inhibitors and sacubitril/valsartan both increase bradykinin; concurrent use
markedly raises angioedema risk, necessitating a 36-hour washout. Hyperkalemia, hypotension,
and renal effects are concerns but are not the primary reason for the washout.
Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient receiving warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which parameter requires the most immediate and frequent
monitoring?
A. Serum creatinine and potassium
B. INR and signs of bleeding CORRECT
C. Platelet count and hemoglobin
D. Liver function tests and bilirubin
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism
and increasing INR/bleeding risk. While renal function and potassium may be affected, the most
critical immediate monitoring is INR and bleeding signs.
Page 2
, Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient with major depressive disorder is homozygous for CYP2D6 poor
metabolizer status. Which antidepressant is most likely to require a significantly
reduced dose or alternative therapy?
A. Sertraline
B. Fluoxetine
C. Venlafaxine CORRECT
D. Bupropion
RATIONALE: Venlafaxine is primarily metabolized by CYP2D6; poor metabolizers have higher
parent drug exposure and increased adverse effects. Sertraline and fluoxetine are also CYP2D6
substrates but have more complex metabolism; bupropion is primarily CYP2B6.
Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
Which pharmacokinetic parameter is most directly altered by advanced chronic
kidney disease (CrCl < 20 mL/min) when prescribing a drug that is 90% renally
eliminated?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life CORRECT
D. Protein binding
RATIONALE: Reduced renal clearance increases elimination half-life, requiring dose adjustment.
Volume of distribution and bioavailability may be affected by other factors, but half-life is the most
direct consequence of decreased renal elimination.
Page 3
BUNDLED QUIZ 1,2,3,4,5,6,7,8 & AND CORRECT ANSWERS PLUS
RATIONALE WELL ILLUSTRATED NEW UPDATE 2026-2027 UTA
49 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to individualize drug therapy across diverse
patient populations
2 Analyze drug-drug, drug-disease, and drug-gene interactions to prevent adverse outcomes and optimize
therapeutic regimens
3 Synthesize current national guidelines and evidence to select, monitor, and adjust pharmacologic therapy
for acute and chronic conditions
4 NURS 5334 Advanced Pharmacology NP Board Exam BUNDLED Quiz 1
5 8 & and Correct Answers plus Rationale Well Illustrated New Update 2026
6 2027 UTA
7 Foundations of Advanced Pharmacology for Nurse Practitioners
8 Applied Advanced Pharmacology for Nurse Practitioners
9 Advanced Advanced Pharmacology for Nurse Practitioners
10 Advanced Pharmacology for Nurse Practitioners Review
ABSTRACT
This study document brings together 49 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology NP Board Exam BUNDLED Quiz 1,2,3,4,5,6,7,8 & and Correct Answers
plus Rationale Well Illustrated New Update 2026-2027 UTA, with the strongest emphasis placed on
Apply pharmacokinetic and pharmacodynamic principles to individualize drug therapy across
diverse patient populations, Analyze drug-drug, drug-disease, and drug-gene interactions to
prevent adverse outcomes and optimize therapeutic regimens, Synthesize current national
guidelines and evidence to select, monitor and and adjust pharmacologic therapy for acute and
chronic conditions. Every item follows the wording style and level of reasoning you meet in the real
paper, and each one is paired with a clear rationale so the correct choice is never a guess. Work
through the set at your own pace, mark the questions that slow you down, then come back to them
until the reasoning feels automatic. Learners who revise this way walk into the exam room
recognising the pattern behind the questions instead of meeting them for the first time. Keep going
- steady, honest practice is what turns a difficult paper into a comfortable pass.
Page 1
,Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient with heart failure with reduced ejection fraction (HFrEF) is initiated on
sacubitril/valsartan. Which mechanism best explains the need for a 36-hour
washout period when transitioning from an ACE inhibitor?
A. Prevention of bradykinin accumulation and angioedema CORRECT
B. Avoidance of hyperkalemia from dual RAAS blockade
C. Reduction of hypotension from combined vasodilation
D. Prevention of renal function deterioration from prostaglandin inhibition
RATIONALE: ACE inhibitors and sacubitril/valsartan both increase bradykinin; concurrent use
markedly raises angioedema risk, necessitating a 36-hour washout. Hyperkalemia, hypotension,
and renal effects are concerns but are not the primary reason for the washout.
Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient receiving warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which parameter requires the most immediate and frequent
monitoring?
A. Serum creatinine and potassium
B. INR and signs of bleeding CORRECT
C. Platelet count and hemoglobin
D. Liver function tests and bilirubin
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, reducing warfarin metabolism
and increasing INR/bleeding risk. While renal function and potassium may be affected, the most
critical immediate monitoring is INR and bleeding signs.
Page 2
, Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
A patient with major depressive disorder is homozygous for CYP2D6 poor
metabolizer status. Which antidepressant is most likely to require a significantly
reduced dose or alternative therapy?
A. Sertraline
B. Fluoxetine
C. Venlafaxine CORRECT
D. Bupropion
RATIONALE: Venlafaxine is primarily metabolized by CYP2D6; poor metabolizers have higher
parent drug exposure and increased adverse effects. Sertraline and fluoxetine are also CYP2D6
substrates but have more complex metabolism; bupropion is primarily CYP2B6.
Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO INDIVIDUALIZE
DRUG THERAPY ACROSS DIVERSE PATIENT POPULATIONS
Which pharmacokinetic parameter is most directly altered by advanced chronic
kidney disease (CrCl < 20 mL/min) when prescribing a drug that is 90% renally
eliminated?
A. Volume of distribution
B. Bioavailability
C. Elimination half-life CORRECT
D. Protein binding
RATIONALE: Reduced renal clearance increases elimination half-life, requiring dose adjustment.
Volume of distribution and bioavailability may be affected by other factors, but half-life is the most
direct consequence of decreased renal elimination.
Page 3
